Aromasin« (Exemestane) was approved in China for adjuvant treatment of postmenopausal women
with estrogen receptor (ER) positive early invasive breast cancer who have received 2-3
years of tamoxifen & are switched to Aromasin« for completion of a total of 5 consecutive
years of adjuvant hormonal therapy by State Food and Drug Administration (SFDA) with
clinical trial waive. While Aromasin« has been used in China for adjuvant therapy of breast
cancer since then, there is currently lack of systematic collection and analysis for the
efficacy and safety data of Aromasin« adjuvant setting in Chinese population. The Aromasin«
Non-Interventional Study is being proposed to collect data systematically and to assess the
efficacy and safety of Aromasin┬« adjuvant setting in Chinese population.
Minimum age: 18 Years.
Maximum age: N/A.
- Early invasive breast cancer (T1-4N1-3M0) confirmed by histology or cytology.
- ER positive.
- The patient must be postmenopausal woman.
- The patient has received adjuvant Tamoxifen therapy for up to 2-3 years and will
switch to receive Aromasin┬« treatment (The decision to prescribe Aromasin┬« will
necessarily precede and will be independent of the decision to enroll patients in the
- Following the adjuvant Tamoxifen therapy for 2-3 years and prior to receiving
Aromasin┬« treatment, there is evidence of a local relapse or distant metastasis of
breast cancer, or a second primary cancer.
- Following the adjuvant Tamoxifen therapy for 2-3 years and received other aromatase
inhibitors (not Aromasin┬«).
307 Hospital of PLA, Beijing 100071, China; Not yet recruiting
Cancer Institute and Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing 100021, China; Recruiting
China-Japan Friendship Hospital, Beijing, China; Recruiting
Peking University Third Hospital/Department of Oncology, Beijing 100191, China; Recruiting
West China Hospital, Sichuan University/ Thyroid & Breast Department, Chengdu 610041, China; Recruiting
The First Affiliated Hospital of Anhui Medical University, Hefei, China; Recruiting
Fudan University Shanghai Cancer center/Department of Breast Surgery, Shanghai 200032, China; Recruiting
Yangpu District Central Hospital, Shanghai 200090, China; Recruiting
Tianjin Oncology Hospital /Department of Breast Surgery, Tianjin 300060, China; Recruiting
Beijing Cancer Hospital, Beijing, Beijing, China; Recruiting
The First Hospital Affiliated to Chongqing Medical University, Chongqing, Chongqing 400016, China; Recruiting
The Second Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong 510260, China; Recruiting
ShenZhen Second Hospital/Department of Breast Surgery, Shenzhen, Guangdong 518035, China; Recruiting
Surgery department of Hebei Cancer Hospital, Shijiazhuang, Hebei 050011, China; Recruiting
Henan Cancer Hospital, Zhenzhou, Henan, China; Recruiting
Breast and thyroid surgery Department, Changsha, Hunan 410005, China; Recruiting
Xiangya Hospital Centre-South University /Department of Breast, Changsha, Hunan, China; Recruiting
Jiangsu Province Hospital/ Surgery Department, Nanjing, Jiangsu 210029, China; Recruiting
Jiansu Cancer Hospital/ Surgery Department, Nanjing, Jiangsu 210000, China; Recruiting
Suzhou Municipal Hospital, Suzhou, Jiangsu 215002, China; Recruiting
The First Affiliated Hospital of Xi'an Jiaotong University/Oncology Surgery, Xi'an, Shaanxi 710061, China; Recruiting
Xijing Hospital, Xi'an, Shaanxi 710032, China; Recruiting
Sichuan Provincial People's Hospital, Chendu, Sichuan 610072, China; Recruiting
Xinjiang Cancer Hospital, Urumqi, Xinjiang 830000, China; Recruiting
Zhejiang Cancer Hospital/Breast Oncology, Hangzhou, Zhejiang 310022, China; Recruiting